Teladoc Health Q4 EPS Estimate Decreased by Leerink Partnrs

Teladoc Health, Inc. (NYSE:TDOC) – Stock analysts at Leerink Partnrs lowered their Q4 2024 earnings per share (EPS) estimates for shares of Teladoc Health in a research note issued to investors on Wednesday, October 30th. Leerink Partnrs analyst M. Cherny now anticipates that the health services provider will earn ($0.19) per share for the quarter, down from their prior estimate of ($0.15). The consensus estimate for Teladoc Health’s current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Teladoc Health’s Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at ($0.65) EPS.

TDOC has been the topic of several other research reports. JPMorgan Chase & Co. dropped their price objective on Teladoc Health from $16.00 to $9.00 and set a “neutral” rating on the stock in a report on Monday, August 26th. Royal Bank of Canada lifted their price target on Teladoc Health from $9.00 to $10.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Piper Sandler decreased their price objective on Teladoc Health from $25.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. TD Cowen cut their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Thursday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price target on shares of Teladoc Health in a research note on Tuesday, August 20th. Fourteen equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $11.97.

Teladoc Health Trading Up 2.3 %

NYSE TDOC opened at $9.21 on Monday. The firm’s fifty day moving average price is $8.48 and its 200 day moving average price is $9.66. Teladoc Health has a 12 month low of $6.76 and a 12 month high of $22.54. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.66 and a quick ratio of 1.62. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -1.60 and a beta of 0.90.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.10. The company had revenue of $640.51 million for the quarter, compared to analyst estimates of $630.50 million. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 9.40%.

Insider Transactions at Teladoc Health

In other Teladoc Health news, CFO Mala Murthy sold 8,750 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total transaction of $62,650.00. Following the completion of the transaction, the chief financial officer now owns 85,767 shares of the company’s stock, valued at approximately $614,091.72. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Teladoc Health news, CFO Mala Murthy sold 8,750 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total transaction of $62,650.00. Following the transaction, the chief financial officer now owns 85,767 shares of the company’s stock, valued at $614,091.72. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Thomas Mckinley bought 7,000 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was acquired at an average cost of $7.57 per share, for a total transaction of $52,990.00. Following the purchase, the director now owns 31,077 shares in the company, valued at approximately $235,252.89. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 35,051 shares of company stock valued at $257,565. Corporate insiders own 0.95% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TDOC. Signaturefd LLC boosted its holdings in shares of Teladoc Health by 148.7% during the second quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock valued at $28,000 after acquiring an additional 1,715 shares during the period. International Assets Investment Management LLC acquired a new position in Teladoc Health during the 2nd quarter valued at about $29,000. Blue Trust Inc. grew its position in Teladoc Health by 84.5% in the 3rd quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider’s stock worth $40,000 after purchasing an additional 1,854 shares during the last quarter. Doheny Asset Management CA bought a new stake in shares of Teladoc Health during the second quarter valued at approximately $46,000. Finally, SageView Advisory Group LLC bought a new stake in shares of Teladoc Health during the first quarter valued at approximately $48,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.